Who is sponsoring NCT00652795?

NCT00652795 is sponsored by Par Pharmaceutical, Inc..

What drugs are being tested in NCT00652795?

Interventions in NCT00652795: Doxycycline Monohydrate, Monodox.

What condition does NCT00652795 study?

NCT00652795 studies To Determine Bioequivalence Under Fasting Conditions.

Is NCT00652795 still recruiting?

NCT00652795 is currently completed. Last updated 1 April 2008.

Last reviewed 2008-04-01 · How we verify

NCT00652795

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized, 2-Way Crossover, Bioequivalence Study of Doxycycline 150 mg Tablet and Monodox 50 mg Capsule Administered as 1 x 150 mg Tablet or 3 x 50 mg Capsules in Healthy Subjects Under Fasting Conditions

Completed Phase 1 Last updated 1 April 2008

What this trial tests

Phase 1 trial testing Doxycycline Monohydrate in To Determine Bioequivalence Under Fasting Conditions in 36 participants. Completed in 1 September 2004.

Timeline

1 July 2004

Primary endpoint
1 September 2004

1 September 2004

Quick facts

Lead sponsor	Par Pharmaceutical, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Enrollment	36
Start date	1 July 2004
Primary completion	1 September 2004
Estimated completion	1 September 2004
Sites	1 location across Canada

Drugs / interventions tested

Doxycycline Monohydrate
Monodox — full drug profile →

Conditions studied

To Determine Bioequivalence Under Fasting Conditions — all drugs for To Determine Bioequivalence Under Fasting Conditions →

Sponsor

Par Pharmaceutical, Inc. — full company profile →

Who can join

18 and older, any sex, with To Determine Bioequivalence Under Fasting Conditions. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Rate and extent of absorption
Time frame: 24 hours

Sponsor's own description

To compare the rate and extent of absorption of doxycycline tablet (Par) versus doxycycline capsule (Monodox)(Oclassen).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00652795 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Par Pharmaceutical, Inc.
Last refreshed: 1 April 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00652795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing